EN DE
Watch Genesystem Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genesystem Co. Ltd. (363250) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Genesystem Co. Ltd. stock KRW 2,749, price KRW 4,100, that is 32.9% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

GC Genesystem Co. Ltd. logo Thin data Nov 16, 2026

Genesystem Co. Ltd.

363250 · KQ

Expensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value 2,749 KRW · Overvalued 
Quality 30/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −50.8 %/yr in KRW) 
Negative free cash flow 
Trails peers (1/8) 
Narrow moat 3/100 · thin data
Thin data 
Estimate
Watch Genesystem Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

31,900 KRW 2,995 KRW Fair Value 2,749 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 2,995 KRW – 31,900 KRW · fair‑value band 2,062 KRW – 3,437 KRW · the 4,100 KRW price screens above the 2,749 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Genesystem Co. in your weekly email

Every Wednesday you see whether Genesystem Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents.

Show moreShow less

It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.

The company was incorporated in 2010 and is based in Daejeon, South Korea.

Stock analysis

Genesystem Co. Ltd. (363250) currently trades at 4,100 KRW, while our estimate is 2,749 KRW, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,062 KRW (bear) to 3,437 KRW (bull), the price of 4,100 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Genesystem Co. Ltd. reported revenue of 381M KRW in FY2025 versus 13.2B KRW in FY2021, a compound −58.8%/yr. Reported net income was −12.0B KRW in FY2025.

Key figures

Market cap 34.0B KRW (≈ $25.4M) Micro · P/S ratio 35.6 · EPS (TTM) −1,241 KRW · Return on equity −86.8% · Return on assets (EBIT) −27.4% (5-year average) · Operating margin −222% · Revenue (TTM) 1.0B KRW · Revenue growth (YoY) +523%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −33%, 363250 screens richer than that median.

Fair Value

Bear 2,062 KRW Fair Value 2,749 KRW Bull 3,437 KRW
Price 4,100 KRW · Downside -32.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−68.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−52.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−50.8%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.1% (2020) → −2,540.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

363250 screens overvalued: fair value 33% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Genesystem Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −32.9% · Below median
Profitability
Return on assets −83.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 523.0% · Top 25%
Balance sheet
Debt / equity 0.25× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 4.33× · Pricier than median
P/S (12 months) 33.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 9
HEALTH (low debt)88 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $198.00 $227.71 +15% vs 363250
WuXi AppTec Co 603259 ¥146.07 ¥164.66 +13% vs 363250
IQVIA Holdings IQV $264.73 $291.63 +10% vs 363250
Thermo Fisher Scientific Inc TMO $691.33 $686.04 −1% vs 363250
Danaher Corporation DHR $229.91 $209.18 −9% vs 363250
IDEXX Laboratories, Inc IDXX $700.65 $496.48 −29% vs 363250
Lonza Group LONN CHF 663.00 CHF 259.80 −61% vs 363250
Mettler-Toledo International Inc MTD $1,727 $655.06 −62% vs 363250
Agilent Technologies, Inc A $172.92 $64.20 −63% vs 363250
Waters Corporation WAT $453.42 $91.26 −80% vs 363250

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genesystem Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genesystem Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/363250

Frequently asked questions

Is Genesystem Co. Ltd. (363250) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 2,749 KRW versus a price of 4,100 KRW, about 33% lower (overvalued).
What is the fair value of 363250?
Our estimate for Genesystem Co. Ltd. is 2,749 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 4,100 KRW.
What is the quality score of 363250?
Genesystem Co. Ltd. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genesystem Co. Ltd. (363250)?
Our calculated price target is the estimate of 2,749 KRW (as of Nov 16, 2026). Cautious scenario 2,062 KRW, optimistic scenario 3,437 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Genesystem Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 2,749 KRW, about 33% lower versus a price of 4,100 KRW (overvalued). Cautious scenario 2,062 KRW, optimistic scenario 3,437 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genesystem Co. Ltd. (363250)?
Genesystem Co. Ltd. reported trailing-twelve-month revenue of about 1.0B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Genesystem Co. Ltd. (363250)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genesystem Co. Ltd. it is 2,749 KRW per share (as of Nov 16, 2026), against a price of 4,100 KRW.
Is Genesystem Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 363250 trades above its calculated fair value: price 4,100 KRW, fair value 2,749 KRW, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 363250?
No. The price is what the market pays today (4,100 KRW); the fair value is what the company's own numbers justify (2,749 KRW). For Genesystem Co. Ltd. the two are 1,351 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genesystem Co. Ltd. worth?
The market values Genesystem Co. Ltd. at about 34.0B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 4,100 KRW; our models calculate a fair value of 2,749 KRW per share.
What do the bullish and bearish scenarios say about 363250?
Our models span a range for Genesystem Co. Ltd.: cautious scenario 2,062 KRW, base 2,749 KRW, optimistic 3,437 KRW per share (as of Nov 16, 2026, price 4,100 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genesystem Co. Ltd. (363250)?
Balance-sheet figures for Genesystem Co. Ltd. (as of Nov 16, 2026): return on equity −86.8%, debt of 0.25 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 363250 from its 52-week high?
Genesystem Co. Ltd. trades at 4,100 KRW, about 41% below its 52-week high of 6,990 KRW and 37% above the low of 2,995 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 2,749 KRW is for.
Which stocks are comparable to Genesystem Co. Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genesystem Co. Ltd. stock attractive at the current price?
The data as of Nov 16, 2026: price 4,100 KRW, calculated fair value 2,749 KRW (−33%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Genesystem Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genesystem Co. Ltd. (363250)?
The closing price on Nov 17, 2026 was 4,100 KRW. Our estimate is 2,749 KRW, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genesystem Co. Ltd. right now?
The price sits above even our optimistic bull case (3,437 KRW). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Genesystem Co. Ltd.

How large is the market capitalisation of Genesystem Co. Ltd. (363250)?
The market capitalisation of Genesystem Co. Ltd. is 34.0B KRW (≈ $25.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genesystem Co. Ltd. (363250)?
The price-to-sales ratio of Genesystem Co. Ltd. is 35.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genesystem Co. Ltd. (363250)?
Earnings per share at Genesystem Co. Ltd. are −1,241 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Genesystem Co. Ltd. (363250)?
The return on equity (ROE) of Genesystem Co. Ltd. is −86.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genesystem Co. Ltd. (363250)?
On an EBIT basis the return on assets of Genesystem Co. Ltd. is −27.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genesystem Co. Ltd. (363250)?
The operating margin of Genesystem Co. Ltd. is −222% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genesystem Co. Ltd. (363250)?
Revenue at Genesystem Co. Ltd. is growing 523% versus a year earlier (3y avg −52.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genesystem Co. Ltd. (363250) generate?
The free cash flow of Genesystem Co. Ltd. is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genesystem Co. Ltd. (363250) carry?
The net debt of Genesystem Co. Ltd. is 2.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genesystem Co. Ltd. in the live analysis

One click puts Genesystem Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.